Biggest News Aggregation in the World
📰 Ben Brahim News

Ben Brahim News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Ben Brahim. Real-time updates on events, politics, business and more.

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the

­ Promising data from ongoing clinical trials of neoantigen cancer vaccine TG4050 and HPV-positive cancer therapeutic vaccine TG4001 presented at key congresses in H1 2023­ Immunogenicity clinical data from ongoing trials confirm mechanism of action of Transgene’s therapeutic vaccines TG4050 and TG4001­ Transgene pl...
United Kingdom United States Lucie Larguier Christian Ottensmeier Ben Brahim Johnc Bell

Transgene provides business update and Q1 2023 financial position

Transgene provides business update and Q1 2023 financial position Dr. Alessandro Riva, MD, appointed as the Company’s Chairman and CEO to accelerate the development of Transgene’s innovative immunotherapy portfolio New clinical data to be communicated in Q2 2023 on TG4001, TG4050...
Ben Brahim Carol Stuckley Christian Ottensmeier Alessandro Riva Pedro Romero Johnc Bell

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

New Data Shows Promising Immunogenecity & Efficacy Profile of Transgene & NEC's Individualized Cancer Vaccine TG4050

New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 - New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an ...
United States United Kingdom Alexandra Martinez Masamitsu Kitase Transgene Euronext Institut Curie

New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023

New Phase I data confirm promising immunogenicity and efficacy profile of TG4050, an individualized neoantigen cancer vaccine developed by Transgene in collaboration with NEC Corporation In the head
United States France General United Kingdom Institut Curie Alexandra Martinez Lucie Larguier

Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC)
United States Transgene Euronext Lucie Larguier Ben Brahim Corporate Communications American Association For Cancer Research

Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by

Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC)STRASBOURG, France--(BUSINESS WIRE)--#HBV--Regulatory News:Transgene (Euronext Paris: TNG), a biotech company that desi...
United States Ben Brahim Lucie Larguier Transgene Euronext Corporate Communications American Association For Cancer Research

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science